Acadia Healthcare Company, Inc. is the largest stand-alone behavioral health company in the United States, specializing in psychiatric and chemical dependency services. The company operates a comprehensive continuum of care through a network of over 250 facilities, encompassing acute inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and comprehensive treatment centers (CTCs). Acadia's inpatient facilities provide high-acuity care for individuals with severe mental health and substance use disorders, while its CTCs make it the largest operator of methadone clinics in the U.S., offering medication-assisted treatment for opioid addiction. Revenue is primarily generated through patient care services, which are reimbursed by commercial insurers, Medicare, Medicaid, and self-pay patients. The company's single reportable segment is behavioral healthcare services, with acute inpatient psychiatric facilities contributing the majority of its revenue. Acadia expands its footprint through a multi-pronged growth strategy that includes de novo facility developments, strategic acquisitions, bed additions at existing facilities, and joint ventures with major non-profit health systems (such as Geisinger Health and Henry Ford Health) to manage their behavioral health operations. Geographically, Acadia's operations are concentrated entirely within the United States and Puerto Rico, following the strategic divestiture of its United Kingdom operations in 2021 to focus exclusively on domestic growth opportunities.
